Antibiogram & Biofilm Formation of Bacteria Causing Prosthetic Joint

Status Not yet recruiting

Clinical Trial Summary

1. Setting of antibiogram in orthopedic department 2. Evaluate the production of biofilm in bacteria isolated from specimens phenotypically and genotypically.

Clinical Trial Description

Increased use of total joint arthroplasties will naturally result in a related increase in the number of prosthetic joint infections (PJIs). PJI is a disastrous complication of orthopedic surgery, frequently leading to prolonged morbidity and increased mortality. Moreover, therapy for PJI is associated with enormous costs. PJI results from numerous factors that lead to inability of periprosthetic immune cells to protect implant surfaces and tissues from bacterial colonization. The most destabilizing factor is the ability of bacteria to adhere to and survive on virtually all natural and synthetic surfaces. Once firmly attached to the surface of an implant, the microorganisms initiate "biofilm" formation, which is a complex of microbial cells embedded in an extracellular matrix composed of proteins, extracellular DNA, and exopolysaccharides, providing protection for bacteria and making them extremely resistant to the immune system and antibiotic. An ineffective empiric antibiotic regimen can be harmful to patients while unnecessary broad-spectrum antibiotics lead to increased resistance. However, healthcare providers often select an antibiotic regimen before bacterial antibiotic sensitivities are available. The Clinical and Laboratory of Standards Institute publishes the M39 Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline, which is a referenced guideline on how to create antibiograms. The antibiogram has multiple uses, including providing guidance for empiric antibiotic therapy, monitoring changes in resistance over time, assisting in formulary decisions and supports antimicrobial stewardship programs to reduce multidrug resistant organisms and the risks of adverse drug events. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05239312
Study type	Observational
Source	Assiut University
Contact	Amina Abd El Aal Mohammed
Phone	01006956223
Email	amina.makhlouf.26@gmail.com
Status	Not yet recruiting
Phase
Start date	March 2022
Completion date	May 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04067843` - Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study	N/A
Enrolling by invitation	`NCT05247281` - NGS vs Culture Outcomes for Treatment of PJI	N/A
Withdrawn	`NCT05269121` - Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections	Phase 1/Phase 2
Recruiting	`NCT02801253` - Cohort of Prosthetic Joint Infections
Completed	`NCT03694925` - Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty
Completed	`NCT03721328` - Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation	Phase 2
Withdrawn	`NCT04787250` - Bacteriophage Therapy in Patients With Prosthetic Joint Infections	Phase 1/Phase 2
Recruiting	`NCT03307109` - Quality of Life in Patients Having a Prosthetic Joint Infection
Recruiting	`NCT04661345` - Identification of Molecular Marker of Coagulase-negative Staphylococci for the Diagnosis of Prosthetic Joint Infections
Recruiting	`NCT02805803` - Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection.	N/A
Completed	`NCT02413034` - The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures	N/A
Recruiting	`NCT03784807` - New Strategies for Biofilm Related Infections
Completed	`NCT04662632` - Abbreviated Protocol for Two-Stage Exchange	Phase 2
Not yet recruiting	`NCT04390607` - Leukocyte Esterase Sensor Test
Recruiting	`NCT04650607` - Phage Safety Cohort Study
Active, not recruiting	`NCT04946500` - Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)
Recruiting	`NCT04762706` - Measuring Distress in Prosthetic Joint Infection Using a Standardized Metric: CRUTCH Pathway Pilot.	N/A
Withdrawn	`NCT05269134` - Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI)	Phase 2
Completed	`NCT04294862` - Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty	Phase 1
Recruiting	`NCT05060952` - Calprotectin in Chronic Prosthetic Joint Infection

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Antibiogram and Biofilm Formation of Bacteria Causing Prosthetic Joint Infections Isolated From Assiut University Hospital

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms